Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.73M P/E - EPS this Y 34.00% Ern Qtrly Grth -
Income -106.81M Forward P/E -8.35 EPS next Y 22.50% 50D Avg Chg 9.00%
Sales 14.02M PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 6.24 EPS next 5Y - 52W High Chg -23.00%
Recommedations 1.40 Quick Ratio 6.53 Shares Outstanding 59.97M 52W Low Chg 223.00%
Insider Own 16.92% ROA -20.81% Shares Float 43.80M Beta 1.88
Inst Own 48.45% ROE -156.45% Shares Shorted/Prior 5.48M/3.24M Price 7.10
Gross Margin -63.54% Profit Margin - Avg. Volume 259,943 Target Price 35.33
Oper. Margin -362.02% Earnings Date Aug 7 Volume 70,175 Change -2.07%
About Immunome, Inc.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc. News
05/17/24 Immunome Announces Promotion of Max Rosett to Chief Financial Officer
05/14/24 Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
05/14/24 Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
05/08/24 Immunome to Present at 2024 Bank of America Healthcare Conference
05/02/24 Immunome Appoints Kinney Horn as Chief Business Officer
04/26/24 Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
04/25/24 Immunome Appoints Sandra M. Swain to Board of Directors
04/05/24 Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
04/04/24 New Strong Sell Stocks for April 4th
03/28/24 Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
03/26/24 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
03/26/24 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
03/22/24 Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
03/07/24 Immunome to Participate in the Leerink Partners Global Biopharma Conference
03/01/24 Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
02/20/24 Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/20/24 Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/16/24 Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02/13/24 Immunome Announces Pricing of Public Offering of Common Stock
02/13/24 Immunome Announces Proposed Public Offering of Common Stock
IMNM Chatroom

User Image Skrumpa Posted - 2 hours ago

$IMNM Short at 13.83 Stop at 12.22

User Image shortburner Posted - 2 days ago

$IMNM Da pig is buying!

User Image intratio Posted - 3 days ago

https://www.intratio.com/stock-forecast/IMNM The artificial intelligence assessed that the price action of this stock has a clearly unfavorable short-term setup and is facing massive downsides in the longer term $IMNM

User Image Jeff9905 Posted - 4 days ago

$IMNM wow. Poor slobs who got suckered in to the secondary are heading for the hills.

User Image Stock_Titan Posted - 5 days ago

$IMNM Immunome Reports First Quarter 2024 Financial Results and Provides Business Update https://www.stocktitan.net/news/IMNM/immunome-reports-first-quarter-2024-financial-results-and-provides-nyk7u4m4jo06.html

User Image Mansuur Posted - 5 days ago

$IMNM what will happen to this piece of shit

User Image Mansuur Posted - 5 days ago

$IMNM

User Image Elliotwavedave Posted - 1 week ago

$IMNM good volume for a Friday

User Image JoshThe3rd Posted - 1 week ago

$IMNM The estimated average from both the PIPE offering at 5.90 and 20.00 offering combined together would be 10.44. Due to XBI I could see some institution involved in both de-risking. Leadership is top notch here with a good starting pipeline. I have focus on other tickers at the moment, but I plan to add in the future.

User Image vikingforthewin Posted - 2 weeks ago

$IMNM I have 5000 shares of it, diamond hands till 30s

User Image shortburner Posted - 2 weeks ago

$IMNM I see they have cash until 2026. Any near term catalyst?

User Image HunterT Posted - 2 weeks ago

$IMNM selling should be done, now we just need some brave souls to buy all those shares up😂 congrats if you held through that💎🤲🏻

User Image Elliotwavedave Posted - 2 weeks ago

$IMNM lot of staff at my local location yesterday Jeff

User Image Elliotwavedave Posted - 04/30/24

$IMNM the bots are gone and the institutions are watching. Looks like they cleared away most of the bottom feeders with this sell off

User Image vikingforthewin Posted - 04/30/24

$IMNM 🛫

User Image Elliotwavedave Posted - 04/30/24

$IMNM when you know you should have held

User Image DonCorleone77 Posted - 04/30/24

$IMNM Immunome initiated with an Overweight at JPMorgan JPMorgan initiated coverage of Immunome with an Overweight rating and $24 price target. The company is "turning a new page" following a transformational year after a merger and multiple deals, the analyst tells investors in a research note. The firm says Immunome's pipeline now combines a pivotal stage asset and multiple early-stage programs in areas that are of significant investor interest. It finds the story "intriguing," saying AL102 in desmoid tumors is the major driver in valuation today, and the rest of the pipeline is largely overlooked by investors.

User Image MGAP Posted - 04/27/24

$IMNM Thinking about entry mid day- to end of day. Looking primed here. let us see

User Image Durand32 Posted - 04/26/24

$IMNM It's back to where it was when I sold. I missed out on the inexplicable run to $30. I guess I have another chance now, but I still don't see any catalysts coming until next year

User Image Jeff9905 Posted - 04/26/24

$IMNM 62m loss and counting. Not good.

User Image HunterT Posted - 04/25/24

$IMNM hoping it levels off here, little bird told me that the selling should be almost finished 🤞🏻 hopefully a recovery into the 20s and $40 by December 🙏🏻 shares that were locked up became available to the past regime employed and they all wanted out in the last two weeks. Millions of shares sold into the open market! Hopefully it was just a speed bump

User Image Elliotwavedave Posted - 04/25/24

$IMNM Sandra swain from Seagen now on board with board of directors.

User Image Jeff9905 Posted - 04/25/24

$IMNM yep. Gotta step on that 60m loss. Pathetic.

User Image Elliotwavedave Posted - 04/25/24

$IMNM time for the orchestrated algo selloff that starts around 3pm

User Image intratio Posted - 04/24/24

$IMNM The automated equity analyst deduces that the stock price of this company is not likely to rise soon and projects a dramatically gloomy future

User Image Jeff9905 Posted - 04/24/24

$IMNM 60m loss to the poor folks that got suckered into the secondary. Sad.

User Image Mansuur Posted - 04/24/24

$IMNM

User Image Elliotwavedave Posted - 04/24/24

$IMNM those 3 pm short algo selloffs we’ve had lately are interesting.

User Image Jeff9905 Posted - 04/23/24

$IMNM looks like selling far from over. Going back to Sharma days. Will reload at 5.

User Image Mansuur Posted - 04/23/24

$IMNM like trash

Analyst Ratings
JP Morgan Overweight Apr 30, 24
Guggenheim Buy Apr 15, 24
Wedbush Outperform Apr 1, 24
Wedbush Outperform Jan 23, 24
Wedbush Outperform Dec 19, 23
Cantor Fitzgerald Overweight Mar 20, 23
Chardan Capital Buy Mar 17, 23
Cantor Fitzgerald Overweight Oct 29, 21
Chardan Capital Buy Oct 27, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SIEGALL CLAY B President and CEO President and CEO Oct 02 Buy 5.91 169,204 999,996 319,636 10/04/23
Turner Bruce Chief Strategy Offic.. Chief Strategy Officer Oct 02 Buy 5.91 42,300 249,993 42,300 10/04/23
RAPP MICHAEL Director Director Sep 13 Buy 17.92 45,950 823,424 182,780 09/13/21